Management of cytomegalovirus infection and disease in liver transplant recipients

World Journal of Hepatology

Volumn 6, Issue 6, 2014, Pages 370-383

  Bruminhent, Jackrapong ^a   Razonable, Raymund R ^a  

^a MAYO CLINIC   (United States)

Author keywords

Cytomegalovirus; Hepatitis; Outcome; Prophylaxis; Transplantation; Treatment; Valganciclovir

Indexed keywords

EID: 84903743208     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v6.i6.370     Document Type: Review

References (104)

1. Razonable RR, Emery VC. Management of CMV infection and disease in transplant patients. 27-29 February 2004. Herpes 2004; 11: 77-86 [PMID: 15960905]
2. Razonable RR, Paya CV. Herpesvirus infections in transplant recipients: current challenges in the clinical management of cytomegalovirus and Epstein-Barr virus infections. Herpes 2003; 10: 60-65 [PMID: 14759337]
3. Arthurs SK, Eid AJ, Pedersen RA, Dierkhising RA, Kremers WK, Patel R, Razonable RR. Delayed-onset primary cytomegalovirus disease after liver transplantation. Liver Transpl 2007; 13: 1703-1709
4. Gane E, Saliba F, Valdecasas GJ, O'Grady J, Pescovitz MD, Lyman S, Robinson CA. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected]. Lancet 1997; 350: 1729-1733 [PMID: 9413463]
5. Paya C, Humar A, Dominguez E, Washburn K, Blumberg E, Alexander B, Freeman R, Heaton N, Pescovitz MD. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004; 4: 611-620 [PMID: 15023154 DOI: 10.1111/j.1600-6143.2004.00382.x]
6. Fica A, Cervera C, Pérez N, Marcos MA, Ramírez J, Linares L, Soto G, Navasa M, Cofan F, Ricart MJ, Pérez-Villa F, Pumarola T, Moreno A. Immunohistochemically proven cytomegalovirus end-organ disease in solid organ transplant patients: clinical features and usefulness of conventional diagnostic tests. Transpl Infect Dis 2007; 9: 203-210 [PMID: 17511827 DOI: 10.1111/j.1399-3062.2007.00220.x]
7. Paya CV, Hermans PE, Wiesner RH, Ludwig J, Smith TF, Rakela J, Krom RA. Cytomegalovirus hepatitis in liver transplantation: prospective analysis of 93 consecutive orthotopic liver transplantations. J Infect Dis 1989; 160: 752-758 [PMID: 2553824]
8. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002; 34: 1094-1097 [PMID: 11914998 DOI: 10.1086/339329]
9. Razonable RR, van Cruijsen H, Brown RA, Wilson JA, Harmsen WS, Wiesner RH, Smith TF, Paya CV. Dynamics of cytomegalovirus replication during preemptive therapy with oral ganciclovir. J Infect Dis 2003; 187: 1801-1808 [PMID: 12751039 DOI: 10.1086/375194]
10. Singh N, Wagener MM. Strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2006; 144: 456-457; author reply 457 [PMID: 16549866]
11. Singh N, Wannstedt C, Keyes L, Wagener MM, Cacciarelli TV. Who among cytomegalovirus-seropositive liver transplant recipients is at risk for cytomegalovirus infection? Liver Transpl 2005; 11: 700-704 [PMID: 15915496 DOI: 10.1002/lt.20417]
12. Razonable RR. Epidemiology of cytomegalovirus disease in solid organ and hematopoietic stem cell transplant recipients. Am J Health Syst Pharm 2005; 62: S7-S13 [PMID: 15821266]
13. Razonable RR, Rivero A, Rodriguez A, Wilson J, Daniels J, Jenkins G, Larson T, Hellinger WC, Spivey JR, Paya CV. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir. J Infect Dis 2001; 184: 1461-1464 [PMID: 11709790 DOI: 10.1086/324516]
14. Razonable RR, Paya CV. Infections and allograft rejection - intertwined complications of organ transplantation. Swiss Med Wkly 2005; 135: 571-573 [PMID: 16333768]
15. O'Grady JG, Alexander GJ, Sutherland S, Donaldson PT, Harvey F, Portmann B, Calne RY, Williams R. Cytomegalovirus infection and donor/recipient HLA antigens: interdependent co-factors in pathogenesis of vanishing bile-duct syndrome after liver transplantation. Lancet 1988; 2: 302-305 [PMID: 2899720]
16. Noack KB, Wiesner RH, Batts K, van Hoek B, Ludwig J. Severe ductopenic rejection with features of vanishing bile duct syndrome: clinical, biochemical, and histologic evidence for spontaneous resolution. Transplant Proc 1991; 23: 1448-1451 [PMID: 1989260]
17. Ludwig J, Wiesner RH, Batts KP, Perkins JD, Krom RA. The acute vanishing bile duct syndrome (acute irreversible rejection) after orthotopic liver transplantation. Hepatology 1987; 7: 476-483 [PMID: 3552923]
18. Pastacaldi S, Teixeira R, Montalto P, Rolles K, Burroughs AK. Hepatic artery thrombosis after orthotopic liver transplantation: a review of nonsurgical causes. Liver Transpl 2001; 7: 75-81 [PMID: 11172388 DOI: 10.1053/jlts.2001.22040]
19. Madalosso C, de Souza NF, Ilstrup DM, Wiesner RH, Krom RA. Cytomegalovirus and its association with hepatic artery thrombosis after liver transplantation. Transplantation 1998; 66: 294-297 [PMID: 9721795]
20. Eid AJRR. Cytomegalovirus disease in solid organ transplant recipients: advances lead to new challenges and opportunities. Curr Opin Organ Tran 2007; 12: 610-617 [DOI: 10.1097/MOT.0b013e3282f0d386]
21. Peleg AY, Husain S, Qureshi ZA, Silveira FP, Sarumi M, Shutt KA, Kwak EJ, Paterson DL. Risk factors, clinical characteristics, and outcome of Nocardia infection in organ transplant recipients: a matched case-control study. Clin Infect Dis 2007; 44: 1307-1314 [PMID: 17443467 DOI: 10.1086/514340]
22. Mendez JC, Dockrell DH, Espy MJ, Smith TF, Wilson JA, Harmsen WS, Ilstrup D, Paya CV. Human beta-herpesvirus interactions in solid organ transplant recipients. J Infect Dis 2001; 183: 179-184 [PMID: 11120923 DOI: 10.1086/317929]
23. Dockrell DH, Prada J, Jones MF, Patel R, Badley AD, Harmsen WS, Ilstrup DM, Wiesner RH, Krom RA, Smith TF, Paya CV. Seroconversion to human herpesvirus 6 following liver transplantation is a marker of cytomegalovirus disease. J Infect Dis 1997; 176: 1135-1140 [PMID: 9359710]
24. Mendez J, Espy M, Smith TF, Wilson J, Wiesner R, Paya CV. Clinical significance of viral load in the diagnosis of cytomegalovirus disease after liver transplantation. Transplantation 1998; 65: 1477-1481 [PMID: 9645806]
25. Razonable RR, Rivero A, Brown RA, Hart GD, Espy MJ, van Cruijsen H, Wilson J, Groettum C, Kremers W, Smith TF, Paya CV. Detection of simultaneous beta-herpesvirus infections in clinical syndromes due to defined cytomegalovirus infection. Clin Transplant 2003; 17: 114-120 [PMID: 12709076]
26. Humar A, Washburn K, Freeman R, Paya CV, Mouas H, Alecock E, Razonable RR. An assessment of interactions between hepatitis C virus and herpesvirus reactivation in liver transplant recipients using molecular surveillance. Liver Transpl 2007; 13: 1422-1427 [PMID: 17902128 DOI: 10.1002/lt.21266]
27. Humar A, Kumar D, Raboud J, Caliendo AM, Moussa G, Levy G, Mazzulli T. Interactions between cytomegalovirus, human herpesvirus-6, and the recurrence of hepatitis C after liver transplantation. Am J Transplant 2002; 2: 461-466 [PMID: 12123213]
28. Rosen HR, Chou S, Corless CL, Gretch DR, Flora KD, Boudousquie A, Orloff SL, Rabkin JM, Benner KG. Cytomegalovirus viremia: risk factor for allograft cirrhosis after liver transplantation for hepatitis C. Transplantation 1997; 64: 721-726 [PMID: 9311709]
29. Razonable RR, Burak KW, van Cruijsen H, Brown RA, Charlton MR, Smith TF, Espy MJ, Kremers W, Wilson JA, Groettum C, Wiesner R, Paya CV. The pathogenesis of hepatitis C virus is influenced by cytomegalovirus. Clin Infect Dis 2002; 35: 974-981 [PMID: 12355385 DOI: 10.1086/342911]
30. Singh N, Husain S, Carrigan DR, Knox KK, Weck KE, Wagener MM, Gayowski T. Impact of human herpesvirus-6 on the frequency and severity of recurrent hepatitis C virus hepatitis in liver transplant recipients. Clin Transplant 2002; 16: 92-96 [PMID: 11966777]
31. Burak KW, Kremers WK, Batts KP, Wiesner RH, Rosen CB, Razonable RR, Paya CV, Charlton MR. Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C. Liver Transpl 2002; 8: 362-369 [PMID: 11965581 DOI: 10.1053/jlts.2002.32282]
32. Bosch W, Heckman MG, Pungpapong S, Diehl NN, Shalev JA, Hellinger WC. Association of cytomegalovirus infection and disease with recurrent hepatitis C after liver transplantation. Transplantation 2012; 93: 723-728 [PMID: 22406819 DOI: 10.1097/TP.0b013e3182472876]
33. Van Laecke S, Desideri F, Geerts A, Van Vlierberghe H, Berrevoet F, Rogiers X, Troisi R, de Hemptinne B, Vanholder R, Colle I. Hypomagnesemia and the risk of new-onset diabetes after liver transplantation. Liver Transpl 2010; 16: 1278-1287 [PMID: 21031543 DOI: 10.1002/lt.22146]
34. Arthurs SK, Eid AJ, Pedersen RA, Kremers WK, Cosio FG, Patel R, Razonable RR. Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation. Clin Infect Dis 2008; 46: 840-846 [PMID: 18260785 DOI: 10.1086/528718]
35. Limaye AP, Bakthavatsalam R, Kim HW, Randolph SE, Halldorson JB, Healey PJ, Kuhr CS, Levy AE, Perkins JD, Reyes JD, Boeckh M. Impact of cytomegalovirus in organ transplant recipients in the era of antiviral prophylaxis. Transplantation 2006; 81: 1645-1652 [PMID: 16794529 DOI: 10.1097/01. tp.0000226071.12562.1a]
36. Hodson EM, Barclay PG, Craig JC, Jones C, Kable K, Strippoli GF, Vimalachandra D, Webster AC. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev 2005;: CD003774 [PMID: 16235341 DOI: 10.1002/14651858.CD003774.pub2]
37. Kalil AC, Levitsky J, Lyden E, Stoner J, Freifeld AG. Metaanalysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2005; 143: 870-880 [PMID: 16365468]
38. Small LN, Lau J, Snydman DR. Preventing post-organ transplantation cytomegalovirus disease with ganciclovir: a metaanalysis comparing prophylactic and preemptive therapies. Clin Infect Dis 2006; 43: 869-880 [PMID: 16941368 DOI: 10.1086/507337]
39. Portela D, Patel R, Larson-Keller JJ, Ilstrup DM, Wiesner RH, Steers JL, Krom RA, Paya CV. OKT3 treatment for allograft rejection is a risk factor for cytomegalovirus disease in liver transplantation. J Infect Dis 1995; 171: 1014-1018 [PMID: 7706779]
40. Winston DJ, Imagawa DK, Holt CD, Kaldas F, Shaked A, Busuttil RW. Long-term ganciclovir prophylaxis eliminates serious cytomegalovirus disease in liver transplant recipients receiving OKT3 therapy for rejection. Transplantation 1995; 60: 1357-1360 [PMID: 8525537]
41. Malek SK, Obmann MA, Gotoff RA, Foltzer MA, Hartle JE, Potdar S. Campath-1H induction and the incidence of infectious complications in adult renal transplantation. Transplantation 2006; 81: 17-20 [PMID: 16421471]
42. Peleg AY, Husain S, Kwak EJ, Silveira FP, Ndirangu M, Tran J, Shutt KA, Shapiro R, Thai N, Abu-Elmagd K, McCurry KR, Marcos A, Paterson DL. Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD-52 antibody. Clin Infect Dis 2007; 44: 204-212 [PMID: 17173218 DOI: 10.1086/510388]
43. Brennan DC, Daller JA, Lake KD, Cibrik D, Del Castillo D. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med 2006; 355: 1967-1977 [PMID: 17093248 DOI: 10.1056/NEJMoa060068]
44. Winston DJ, Wirin D, Shaked A, Busuttil RW. Randomised comparison of ganciclovir and high-dose acyclovir for longterm cytomegalovirus prophylaxis in liver-transplant recipients. Lancet 1995; 346: 69-74 [PMID: 7603215]
45. Sarmiento JM, Dockrell DH, Schwab TR, Munn SR, Paya CV. Mycophenolate mofetil increases cytomegalovirus invasive organ disease in renal transplant patients. Clin Transplant 2000; 14: 136-138 [PMID: 10770418]
46. Demopoulos L, Polinsky M, Steele G, Mines D, Blum M, Caulfield M, Adamkovic A, Liu Q, Harler MB, Hahn C, Singh A. Reduced risk of cytomegalovirus infection in solid organ transplant recipients treated with sirolimus: a pooled analysis of clinical trials. Transplant Proc 2008; 40: 1407-1410 [PMID: 18589118 DOI: 10.1016/j.transproceed.2008.03.084]
47. Vítko S, Margreiter R, Weimar W, Dantal J, Kuypers D, Winkler M, Øyen O, Viljoen HG, Filiptsev P, Sadek S, Li Y, Cretin N, Budde K. Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2005; 5: 2521-2530 [PMID: 16162203 DOI: 10.1111/j. 1600-6143.2005.01 063.x]
48. Kijpittayarit S, Eid AJ, Brown RA, Paya CV, Razonable RR. Relationship between Toll-like receptor 2 polymorphism and cytomegalovirus disease after liver transplantation. Clin Infect Dis 2007; 44: 1315-1320 [PMID: 17443468 DOI: 10.1086/514339]
49. Kang SH, Abdel-Massih RC, Brown RA, Dierkhising RA, Kremers WK, Razonable RR. Homozygosity for the toll-like receptor 2 R753Q single-nucleotide polymorphism is a risk factor for cytomegalovirus disease after liver transplantation. J Infect Dis 2012; 205: 639-646
50. Humar A, Mazzulli T, Moussa G, Razonable RR, Paya CV, Pescovitz MD, Covington E, Alecock E. Clinical utility of cytomegalovirus (CMV) serology testing in high-risk CMV D+/R-transplant recipients. Am J Transplant 2005; 5: 1065-1070 [PMID: 15816887 DOI: 10.1111/j.1600-6143.2005.00797.x]
51. de Rooij BJ, van der Beek MT, van Hoek B, Vossen AC, Rogier Ten Hove W, Roos A, Schaapherder AF, Porte RJ, van der Reijden JJ, Coenraad MJ, Hommes DW, Verspaget HW. Mannose-binding lectin and ficolin-2 gene polymorphisms predispose to cytomegalovirus (re)infection after orthotopic liver transplantation. J Hepatol 2011; 55: 800-807
52. La Rosa C, Krishnan A, Longmate J, Martinez J, Manchanda P, Lacey SF, Limaye AP, Diamond DJ. Programmed death-1 expression in liver transplant recipients as a prognostic indicator of cytomegalovirus disease. J Infect Dis 2008; 197: 25-33 [PMID: 18171281 DOI: 10.1086/523652]
53. Giulieri S, Manuel O. QuantiFERON(R)-CMV assay for the assessment of cytomegalovirus cell-mediated immunity. Expert Rev Mol Diagn 2011; 11: 17-25
54. Kumar D, Chernenko S, Moussa G, Cobos I, Manuel O, Preiksaitis J, Venkataraman S, Humar A. Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients. Am J Transplant 2009; 9: 1214-1222 [PMID: 19422346 DOI: 10.1111/j.1600-6143.2009.02618.x]
55. Kotton CN, Kumar D, Caliendo AM, Asberg A, Chou S, Danziger-Isakov L, Humar A. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation 2013; 96: 333-360 [PMID: 23896556 DOI: 10.1097/TP.0b013e31829df29d]
56. Manuel O, Husain S, Kumar D, Zayas C, Mawhorter S, Levi ME, Kalpoe J, Lisboa L, Ely L, Kaul DR, Schwartz BS, Morris MI, Ison MG, Yen-Lieberman B, Sebastian A, Assi M, Humar A. Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multicenter cohort study. Clin Infect Dis 2013; 56: 817-824 [PMID: 23196955 DOI: 10.1093/cid/cis993]
57. Warlé MC, Farhan A, Metselaar HJ, Hop WC, van der Plas AJ, Kap M, de Rave S, Kwekkeboom J, Zondervan PE, IJzermans JN, Tilanus HW, Pravica V, Hutchinson IV, Bouma GJ. In vitro cytokine production of TNFalpha and IL-13 correlates with acute liver transplant rejection. Hum Immunol 2001; 62: 1258-1265 [PMID: 11704289]
58. Fietze E, Prösch S, Reinke P, Stein J, Döcke WD, Staffa G, Löning S, Devaux S, Emmrich F, von Baehr R. Cytomegalovirus infection in transplant recipients. The role of tumor necrosis factor. Transplantation 1994; 58: 675-680 [PMID: 7940686]
59. Cook CH, Trgovcich J, Zimmerman PD, Zhang Y, Sedmak DD. Lipopolysaccharide, tumor necrosis factor alpha, or interleukin-1beta triggers reactivation of latent cytomegalovirus in immunocompetent mice. J Virol 2006; 80: 9151-9158 [PMID: 16940526 DOI: 10.1128/jvi.00216-06]
60. Hooks MA, Perlino CA, Henderson JM, Millikan WJ, Kutner MH. Prevalence of invasive cytomegalovirus disease with administration of muromonab CD-3 in patients undergoing orthotopic liver transplantation. Ann Pharmacother 1992; 26: 617-620 [PMID: 1317228]
61. Bosch W, Heckman MG, Diehl NN, Shalev JA, Pungpapong S, Hellinger WC. Association of cytomegalovirus infection and disease with death and graft loss after liver transplant in high-risk recipients. Am J Transplant 2011; 11: 2181-2189 [PMID: 21827609 DOI: 10.1111/j.1600-6143.2011.03618.x]
62. Singh N, Gayowski T, Wagener MM, Marino IR. Increased infections in liver transplant recipients with recurrent hepatitis C virus hepatitis. Transplantation 1996; 61: 402-406 [PMID: 8610350]
63. Emery VC, Sabin CA, Cope AV, Gor D, Hassan-Walker AF, Griffiths PD. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet 2000; 355: 2032-2036 [PMID: 10885354 DOI: 10.1016/s0140-6736(00)02350-3]
64. Mattes FM, Hainsworth EG, Hassan-Walker AF, Burroughs AK, Sweny P, Griffiths PD, Emery VC. Kinetics of cytomegalovirus load decrease in solid-organ transplant recipients after preemptive therapy with valganciclovir. J Infect Dis 2005; 191: 89-92 [PMID: 15593008 DOI: 10.1086/425905]
65. Singh N. Cytomegalovirus infection in solid organ transplant recipients: new challenges and their implications for preventive strategies. J Clin Virol 2006; 35: 474-477 [PMID: 16406798 DOI: 10.1016/j.jcv.2005.10.014]
66. Paya CV, Wilson JA, Espy MJ, Sia IG, DeBernardi MJ, Smith TF, Patel R, Jenkins G, Harmsen WS, Vanness DJ, Wiesner RH. Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: a randomized, placebo-controlled trial. J Infect Dis 2002; 185: 854-860 [PMID: 11920308 DOI: 10.1086/339449]
67. Singh N, Wannstedt C, Keyes L, Gayowski T, Wagener MM, Cacciarelli TV. Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: impact on viral load and late-onset cytomegalovirus disease. Transplantation 2005; 79: 85-90 [PMID: 15714174]
68. Singh N, Paterson DL, Gayowski T, Wagener MM, Marino IR. Cytomegalovirus antigenemia directed pre-emptive prophylaxis with oral versus I.V. ganciclovir for the prevention of cytomegalovirus disease in liver transplant recipients: a randomized, controlled trial. Transplantation 2000; 70: 717-722 [PMID: 11003347]
69. Singh N, Yu VL. Preemptive therapy for cytomegalovirus. Liver Transpl 2006; 12: 327 [PMID: 16447192 DOI: 10.1002/lt.20676]
70. Bodro M, Sabé N, Lladó L, Baliellas C, Niubó J, Castellote J, Fabregat J, Rafecas A, Carratalà J. Prophylaxis versus preemptive therapy for cytomegalovirus disease in high-risk liver transplant recipients. Liver Transpl 2012; 18: 1093-1099 [PMID: 22532316 DOI: 10.1002/lt.23460]
71. Onor IO, Todd SB, Meredith E, Perez SD, Mehta AK, Marshall Lyon G, Knechtle SJ, Hanish SI. Evaluation of clinical outcomes of prophylactic versus preemptive cytomegalovirus strategy in liver transplant recipients. Transpl Int 2013; 26: 592-600 [PMID: 23590709 DOI: 10.1111/tri.12101]
72. Razonable RR, Humar A. Cytomegalovirus in solid organ transplantation. Am J Transplant 2013; 13 Suppl 4: 93-106 [PMID: 23465003 DOI: 10.1111/ajt.12103]
73. Levitsky J, Singh N, Wagener MM, Stosor V, Abecassis M, Ison MG. A survey of CMV prevention strategies after liver transplantation. Am J Transplant 2008; 8: 158-161 [PMID: 17973961 DOI: 10.1111/j.1600-6143.2007.02026.x]
74. Vandecasteele E, De Waele J, Vandijck D, Blot S, Vogelaers D, Rogiers X, Van Vlierberghe H, Decruyenaere J, Hoste E. Antimicrobial prophylaxis in liver transplant patients--a multicenter survey endorsed by the European Liver and Intestine Transplant Association. Transpl Int 2010; 23: 182-190 [PMID: 19793076 DOI: 10.1111/j.1432-2277.2009.00974.x]
75. Hodson EM, Jones CA, Webster AC, Strippoli GF, Barclay PG, Kable K, Vimalachandra D, Craig JC. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials. Lancet 2005; 365: 2105-2115 [PMID: 15964447 DOI: 10.1016/s0140-6736(05)66553-1]
76. Singh N, Wannstedt C, Keyes L, Mayher D, Tickerhoof L, Akoad M, Wagener MM, Cacciarelli TV. Valganciclovir as preemptive therapy for cytomegalovirus in cytomegalovirusseronegative liver transplant recipients of cytomegalovirusseropositive donor allografts. Liver Transpl 2008; 14: 240-244 [PMID: 18236404 DOI: 10.1002/lt.21362]
77. Caliendo AM, St George K, Kao SY, Allega J, Tan BH, La-Fontaine R, Bui L, Rinaldo CR. Comparison of quantitative cytomegalovirus (CMV) PCR in plasma and CMV antigenemia assay: clinical utility of the prototype AMPLICOR CMV MONITOR test in transplant recipients. J Clin Microbiol 2000; 38: 2122-2127 [PMID: 10834964]
78. Razonable RR, Paya CV, Smith TF. Role of the laboratory in diagnosis and management of cytomegalovirus infection in hematopoietic stem cell and solid-organ transplant recipients. J Clin Microbiol 2002; 40: 746-752 [PMID: 11880387]
79. Piiparinen H, Höckerstedt K, Grönhagen-Riska C, Lautenschlager I. Comparison of two quantitative CMV PCR tests, Cobas Amplicor CMV Monitor and TaqMan assay, and pp65-antigenemia assay in the determination of viral loads from peripheral blood of organ transplant patients. J Clin Virol 2004; 30: 258-266 [PMID: 15135746 DOI: 10.1016/j. jcv.2003.12.010]
80. Razonable RR, Åsberg A, Rollag H, Duncan J, Boisvert D, Yao JD, Caliendo AM, Humar A, Do TD. Virologic suppression measured by a cytomegalovirus (CMV) DNA test calibrated to the World Health Organization international standard is predictive of CMV disease resolution in transplant recipients. Clin Infect Dis 2013; 56: 1546-1553 [PMID: 23418272 DOI: 10.1093/cid/cit096]
81. Singh N, Wannstedt C, Keyes L, Wagener MM, Gayowski T, Cacciarelli TV. Indirect outcomes associated with cytomegalovirus (opportunistic infections, hepatitis C virus sequelae, and mortality) in liver-transplant recipients with the use of preemptive therapy for 13 years. Transplantation 2005; 79: 1428-1434 [PMID: 15912115]
82. Winston DJ, Busuttil RW. Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients. Transplantation 2003; 75: 229-233 [PMID: 12548129 DOI: 10.1097/01.tp.0000040601.60276.96]
83. Razonable RR, Paya CV. Valganciclovir for the prevention and treatment of cytomegalovirus disease in immunocompromised hosts. Expert Rev Anti Infect Ther 2004; 2: 27-41 [PMID: 15482169]
84. Pescovitz MD, Rabkin J, Merion RM, Paya CV, Pirsch J, Freeman RB, O'Grady J, Robinson C, To Z, Wren K, Banken L, Buhles W, Brown F. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother 2000; 44: 2811-2815 [PMID: 10991864]
85. Kalil AC, Mindru C, Botha JF, Grant WJ, Mercer DF, Olivera MA, McCartan MA, McCashland TM, Langnas AN, Florescu DF. Risk of cytomegalovirus disease in high-risk liver transplant recipients on valganciclovir prophylaxis: a systematic review and meta-analysis. Liver Transpl 2012; 18: 1440-1447 [PMID: 22887929 DOI: 10.1002/lt.23530]
86. Winston DJ, Saliba F, Blumberg E, Abouljoud M, Garcia-Diaz JB, Goss JA, Clough L, Avery R, Limaye AP, Ericzon BG, Navasa M, Troisi RI, Chen H, Villano SA, Uknis ME. Efficacy and safety of maribavir dosed at 100 mg orally twice daily for the prevention of cytomegalovirus disease in liver transplant recipients: a randomized, double-blind, multicenter controlled trial. Am J Transplant 2012; 12: 3021-3030 [PMID: 22947426 DOI: 10.1111/j.1600-6143.2012.04231.x]
87. Hodson EM, Jones CA, Strippoli GF, Webster AC, Craig JC. Immunoglobulins, vaccines or interferon for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev 2007; (2): CD005129 [PMID: 17443573 DOI: 10.1002/14651858.CD005129.pub2]
88. Humar A, Paya C, Pescovitz MD, Dominguez E, Washburn K, Blumberg E, Alexander B, Freeman R, Heaton N, Mueller B. Clinical utility of cytomegalovirus viral load testing for predicting CMV disease in D+/R-solid organ transplant recipients. Am J Transplant 2004; 4: 644-649 [PMID: 15023158 DOI: 10.1111/j.1600-6143.2004.00391.x]
89. Freeman RB, Paya C, Pescovitz MD, Humar A, Dominguez E, Washburn K, Blumberg E, Alexander B, Heaton N. Risk factors for cytomegalovirus viremia and disease developing after prophylaxis in high-risk solid-organ transplant recipients. Transplantation 2004; 78: 1765-1773
90. Humar A, Lebranchu Y, Vincenti F, Blumberg EA, Punch JD, Limaye AP, Abramowicz D, Jardine AG, Voulgari AT, Ives J, Hauser IA, Peeters P. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant 2010; 10: 1228-1237 [PMID: 20353469 DOI: 10.1111/j.1600-6143.2010.03074.x]
91. Humar A, Limaye AP, Blumberg EA, Hauser IA, Vincenti F, Jardine AG, Abramowicz D, Ives JA, Farhan M, Peeters P. Extended valganciclovir prophylaxis in D+/R-kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: two-year results of the IMPACT study. Transplantation 2010; 90: 1427-1431 [PMID: 21197713]
92. Jain A, Orloff M, Kashyap R, Lansing K, Betts R, Mohanka R, Menegus M, Ryan C, Bozorgzadeh A. Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients? Transplant Proc 2005; 37: 3182-3186
93. Montejo M, Montejo E, Gastaca M, Valdivieso A, Fernandez JR, Testillano M, Gonzalez J, Bustamante J, Ruiz P, Suarez MJ, Ventoso A, Rubio MC, de Urbina JO. Prophylactic therapy with valgancyclovir in high-risk (cytomegalovirus D+/R-) liver transplant recipients: a single-center experience. Transplant Proc 2009; 41: 2189-2191 [PMID: 19715869 DOI: 10.1016/j.transproceed.2009.06.005]
94. Boillat Blanco N, Pascual M, Venetz JP, Nseir G, Meylan PR, Manuel O. Impact of a preemptive strategy after 3 months of valganciclovir cytomegalovirus prophylaxis in kidney transplant recipients. Transplantation 2011; 91: 251-255 [PMID: 21099744 DOI: 10.1097/TP.0b013e318200b9f0]
95. Limaye AP. Ganciclovir-resistant cytomegalovirus in organ transplant recipients. Clin Infect Dis 2002; 35: 866-872
96. Limaye AP. Antiviral resistance in cytomegalovirus: an emerging problem in organ transplant recipients. Semin Respir Infect 2002; 17: 265-273
97. Avery RK, Mossad SB, Poggio E, Lard M, Budev M, Bolwell B, Waldman WJ, Braun W, Mawhorter SD, Fatica R, Krishnamurthi V, Young JB, Shrestha R, Stephany B, Lurain N, Yen-Lieberman B. Utility of leflunomide in the treatment of complex cytomegalovirus syndromes. Transplantation 2010; 90: 419-426 [PMID: 20683281 DOI: 10.1097/TP. 0b013e3181e9 4106]
98. Marty FM, Ljungman P, Papanicolaou GA, Winston DJ, Chemaly RF, Strasfeld L, Young JA, Rodriguez T, Maertens J, Schmitt M, Einsele H, Ferrant A, Lipton JH, Villano SA, Chen H, Boeckh M. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stemcell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. Lancet Infect Dis 2011; 11: 284-292 [PMID: 21414843 DOI: 10.1016/s1473-3099(11)70024-x]
99. Alain S, Revest M, Veyer D, Essig M, Rerolles JP, Rawlinson W, Mengelle C, Huynh A, Kamar N, Garrigue I, Kaminski H, Segard C, Presne C, Mazeron MC, Avettant-Fenoël V, Lecuit M, Lortholary O, Coaquette A, Hantz S, Leruez-Ville M, Ploy MC. Maribavir use in practice for cytomegalovirus infection in French transplantation centers. Transplant Proc 2013; 45: 1603-1607 [PMID: 23726629 DOI: 10.1016/j.transproceed.201 3.01.082]
100. Painter W, Robertson A, Trost LC, Godkin S, Lampert B, Painter G. First pharmacokinetic and safety study in humans of the novel lipid antiviral conjugate CMX001, a broadspectrum oral drug active against double-stranded DNA viruses. Antimicrob Agents Chemother 2012; 56: 2726-2734 [PMID: 22391537 DOI: 10.1128/aac.05983-11]
101. Momméja-Marin HBT, Chittick G. Demographic/Baseline Characteristics of Patients Treated with CMX001 for Serious or Life-threatening Double-stranded DNA (dsDNA) Virus Infections: Predictors of Multiple dsDNA virus Infection. Europeon group for blood and marrow transplantation meeting. London, UK, 2013
102. Chemaly RFEG, Champlin R, Richard M, Zimmermann H, Lischka P, Stoelben S, McCormick D, Ruebsamen-Schaeff H. Letermovir (AIC246) for the Prevention of CMV Infections Meets Primary Endpoint in Phase 2b Trial in Human Blood Precursor Cell Transplant Recipients. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, United States, 2012
103. Kaul DR, Stoelben S, Cober E, Ojo T, Sandusky E, Lischka P, Zimmermann H, Rubsamen-Schaeff H. First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246. Am J Transplant 2011; 11: 1079-1084 [PMID: 21521474 DOI: 10.1111/j.1600-6143.2011.03530.x]
104. Razonable RR. Cytomegalovirus infection after liver transplantation: current concepts and challenges. World J Gastroenterol 2008; 14: 4849-4860 [PMID: 18756591]